Background To investigate the rates of maintenance therapy in advanced non-small cell cancer, the reasons for not progressing to second line therapy at disease progression at our cancer centre and to use this data as a way to institute it into clinical practice in our cancer centre. Method This study was approved by the ethics committee. The data was collected from a purpose built cancer unit...

Systemic therapy improves the survival and quality of life of patients with advanced stage non-small cell lung cancer (NSCLC). Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxic agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab). Efforts to improve the outcome of first-line therapy for advanced and metasta...

The whole world is affected due to pandemic caused by SARS Cov 2. Imposition of nationwide lockdown curb viral transmission has impacted various healthcare services including cancer care services. Most important concern the risk exposure Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) and its effect on patients with cancer. Alteration in lung number chemotherapy sessions, dosages c...

The natural killer (NK) activity against K 562 target cells was explored in 20 children with acute lymphoblastic leukemia (ALL). Three of 5 patients examined at the time of diagnosis had normal NK activity. Two patients, who had more than 80% circulating blasts had significantly low NK activity. The level of NK activity of these 5 patients was inversely proportional to the percentage of blast c...

OBJECTIVE Loss of immunity to previous vaccination and timing of re-vaccination in children receiving chemotherapy remains controversial. The aim of this study was to investigate the immunity to vaccine preventable diseases in children with acute lymphoblastic leukemia (ALL). PROCEDURE Sixty-one patients with ALL and 13 healthy siblings were enrolled. Three study groups included newly diagnos...

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialized world. Despite significant progress in early stage disease, survival rates for advanced disease remain low. Maintenance therapy is a treatment strategy that has been investigated extensively in NSCLC and has been the subject of considerable recent debate. Options for maintenance include continuing the ...

Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma. This report focuses upon treatment efficacy, quality of life, and...

Our objective was to investigate the efficacy and safety of capecitabine maintenance therapy (CMT) after capecitabine-based combination chemotherapy in patients with metastatic breast cancer. The clinical data of 139 metastatic breast cancer patients treated from March 2008 to May 2012 with capecitabine-based combination chemotherapy were retrospectively analyzed. When initial disease control w...

Malignant pleural mesothelioma (MPM) is a lethal disease with poor prognosis. The combination of cisplatin and pemetrexed has been confirmed as the standard of care for nonoperable MPM. Data have shown that the adoption of pemetrexed maintenance therapy (PMT) following first-line treatment appears extremely promising.We describe a 57-year-old man diagnosed as advanced MPM. We treated this patie...

P a folate analogue metabolic inhibitor, has been approved as the first maintenance treatment for locally advanced or metastatic nonsquamous non–small cell lung cancer, the Food and Drug Administration announced. “This drug represents a new approach in the treatment of advanced non–small cell lung cancer,” Dr. Richard Pazdur, director of the FDA’s office of oncology drug products, said in the s...